Form 4: Xeris Biopharma Director Executes Stock Transactions

Director Barbara-Jean Anne Bormann-Kennedy reported the sale of 16,000 shares and the acquisition of 24,193 restricted stock units and 32,996 stock options.

Summary

• Director Barbara-Jean Anne Bormann-Kennedy sold 16,000 shares of common stock at a weighted average price of $6.0942.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on September 12, 2025.
• The director was granted 24,193 restricted stock units (RSUs) and 32,996 stock options with an exercise price of $6.15.
• The new equity awards vest in full on the earlier of June 4, 2026, or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale was pre-planned and offset by new equity grants, reflecting standard director compensation and portfolio management.

Positives

• The director maintains a significant stake of 150,693 shares following the transactions.
• The sale was conducted via a pre-planned Rule 10b5-1 program, indicating a systematic approach rather than reactive selling.

Negatives

• The director reduced their direct holdings by 16,000 shares.

Risks

• Future share price volatility may impact the value of the newly granted stock options and RSUs.
• Vesting of equity awards is contingent upon continued service to the company.

Future Outlook

The director's equity grants are subject to vesting on June 4, 2026, or the next annual meeting, aligning the director's interests with short-term company performance.

Industry Context

StockSavvy.ai notes that insider activity in the biopharma sector is common for compensation purposes, and the use of 10b5-1 plans is a standard governance practice to mitigate concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is considered a best practice for corporate governance among mid-cap biopharmaceutical companies.
• Equity-based compensation for directors is consistent with standard industry practices to ensure alignment with shareholder interests.

Stakeholder Impact

• Shareholders should view the 10b5-1 plan as a sign of disciplined, non-discretionary trading by the director.

Next Steps

• Vesting of restricted stock units and stock options on June 4, 2026.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Director Transactions, Equity Compensation